Heron Therapeutics, Inc. /De/ (NASDAQ: HRTX)

Heron Therapeutics, Inc., or HRTX, is a commercial-stage biotechnology company operating within the healthcare and life sciences industry. The company is dedicated to enhancing patient care through the development and commercialization of innovative therapeutic solutions. Its headquarters are located in the United States, and its operations span across various regions, focusing on acute care and oncology patients.

HRTX's primary business activities revolve around the research, development, and commercialization of pharmaceutical products. These activities are supported by the company's advanced science, patented technologies, and innovative approach to drug discovery and development. The company aims to advance the standard of care for acute care and oncology patients by creating a portfolio of products that address various medical conditions and unmet needs.

The company generates revenue through the sale of its primary products, which include ZYNRELEF, APONVIE, SUSTOL, and CINVANTI. These products are designed to treat a range of conditions, such as postoperative pain management, nausea and vomiting prevention, and chemotherapy-induced nausea and vomiting. ZYNRELEF, for instance, is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and meloxicam, offering extended-release pain relief for up to 72 hours following surgery.

In comparison to its competitors, HRTX stands out due to its innovative product portfolio and patented technologies. The Biochronomer Technology, for example, enables the company to deliver therapeutic levels of various pharmacological agents over extended periods, ensuring consistent drug levels and improved patient outcomes.

Although the text does not explicitly mention specific customers, it is evident that HRTX's products are distributed within the United States through a limited number of specialty distributors and full-line wholesalers. These intermediaries then resell the products to healthcare providers and hospitals, which are the end-users of HRTX's offerings.

Heron Therapeutics' brand names and trade names include ZYNRELEF, APONVIE, SUSTOL, CINVANTI, and Biochronomer Technology. Each of these names represents a unique product or technology that contributes to the company's mission of improving patient care and advancing medical standards.